Warhound launches with $200M to clone and gene-edit US military working dogs, backed by Colossal and Anduril
What's the deal? WarhoundDealroom has a profile for this one. Try Dealroom →, a Texas-based defense tech startup conceived by Colossal Biosciences co-founder Ben Lamm and Anduril founder Palmer Luckey, came out of stealth on 22 October with a $200 million seed round to breed, clone and gene-edit working dogs for the US military, police and first responders. TechCrunch and USA Today report the round values the company at $1.2 billion. Backers include In-Q-Tel, Sequoia Capital, ARK InvestDealroom has a profile for this one. Try Dealroom →, Franklin Templeton, 8VC, Breyer Capital, Lux Capital, Builders VCDealroom has a profile for this one. Try Dealroom → and Bob Nelsen.
The problem it targets. According to the company, more than 80% of US military working dogs are bought from Europe, and after a roughly three-year acquisition and training pipeline fewer than half are ultimately fit for service, so the US must source about 200 dogs to field 100. The Department of War's programme runs more than 2,200 working dog teams.
How it works. Warhound biobanks top-performing dogs (mostly Belgian Malinois, plus shepherds and labs), clones them through Colossal-owned Viagen, and uses gene editing licensed from Colossal to screen out inherited conditions such as hip dysplasia and muscle degeneration; Lamm has floated later enhancements such as wolf olfactory genes. Anduril supplies body armour, eye and ear protection, sensors and integration with its Eagle Eye system. The first puppies are expected in early 2027, with service ideally within about two years. Warhound has no signed customers or pricing yet and is discussing a "Canine-as-a-Service" model with government buyers.
Who runs it. CEO David Spirk is a former Marine and the Pentagon's former chief data officer who most recently worked at Palantir. Lamm sits on the board; neither he nor Luckey is involved day to day. Luckey and Anduril hold no equity, while Colossal owns a stake and licenses its technology.
The bigger picture. Warhound is the latest company to come out of Colossal's de-extinction platform, after Form Bio, Breaking and Astromech, which was valued at $2 billion in March. Colossal itself is reported to be in talks to raise at a valuation of $25 billion to $26 billion led by TWG Global, up from $10.2 billion in January 2025. The launch also extends the defense tech funding wave around Anduril, whose own valuation may reach $90 billion in an employee share sale.
Sources: Warhound press release, TechCrunch, Fortune, WIRED, Financial Times, Axios (Colossal round talks).
